Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

A compound of formula I:

• or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof, wherein:
• U and the two carbon atoms designated by a and f3 together form a 5- or 6-membered aromatic ring having 0-2 nitrogen atoms;
• A is C, CR6, or N;
• B and F are each independently selected from C, CR6, and N, wherein B and F cannot both be N;
• D is selected from N, NR7, O, CR6 or C(R6)2;
• E is N, NR7, CR6 or C(R6)2;
• W is N, NR7, CR6 or C(R6)2;
• X is N, NR7, O, CR6 or C(R6)2;
• Y and Z are each independently selected from C, CR6, and N, wherein Y and Z cannot both be N;
• V is C or CR6,
• or when Z is C or CR6, V is C, CR6, or N;
• wherein when the ring formed by X, Y, Z, V and W is
• then R2 is —OR8, —SR8, or —(CH2)nOR8;
• m and n are independently integers selected from 0-4;
• each occurrence of the bond “” is either a single bond or a double bond;
• each occurrence of R1, R2, R4, and R5 are each independently selected from:
• halogen, —R, —OR, —NO2, —NCS, —CN, —CF3, —OCF3, —SiR3, —N(R)2, —SR, —SOR, —SO2R, —SO2N(R)2, —SO3R, —(CR2)1-3R, —(CR2)1-3—OR, —(CR2)0-3—C(O)NR(CR2)0-3R, —(CR2)0-3—C(O)NR(CR2)0-3OR, —C(O)R, —C(O)C(O)R, —C(O)CH2C(O)R, —C(S)R, —C(S)OR, —C(O)OR, —C(O)C(O)OR, —C(O)C(O)N(R)2, —OC(O)R, —C(O)N(R)2, —OC(O)N(R)2, —C(S)N(R)2, —(CR2)0-3NHC(O)R, —N(R)N(R)COR, —N(R)N(R)C(O)OR, —N(R)N(R)CON(R)2, —N(R)SO2R, —N(R)SO2N(R)2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(S)R, —N(R)C(O)N(R)2, —N(R)C(S)N(R)2, —N(COR)COR, —N(OR)R, —C(═NH)N(R)2, —C(O)N(OR)R, —C(═NOR)R, —OP(O)(OR)2, —P(O)(R)2, —P(O)(OR)2, and —P(O)(H)(OR);
• R3 is absent or is selected from:
• halogen, —R, —OR, —NO2, —NCS, —CN, —CF3, —OCF3, —SiR3, —N(R)2, —SR, —SOR, —SO2R, —SO2N(R)2, —SO3R, —(CR2)1-3R, —(CR2)1-3—OR, —(CR2)0-3—C(O)NR(CR2)0-3R, —(CR2)0-3—C(O)NR(CR2)0-3OR, —C(O)R, —C(O)C(O)R, —C(O)CH2C(O)R, —C(S)R, —C(S)OR, —C(O)OR, —C(O)C(O)OR, —C(O)C(O)N(R)2, —OC(O)R, —C(O)N(R)2, —OC(O)N(R)2, —C(S)N(R)2, —(CR2)0-3NHC(O)R, —N(R)N(R)COR, —N(R)N(R)C(O)OR, —N(R)N(R)CON(R)2, —N(R)SO2R, —N(R)SO2N(R)2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(S)R, —N(R)C(O)N(R)2, —N(R)C(S)N(R)2, —N(COR)COR, —N(OR)R, —C(═NH)N(R)2, —C(O)N(OR)R, —C(═NOR)R, —OP(O)(OR)2, —P(O)(R)2, —P(O)(OR)2, and —P(O)(H)(OR);
• each R6 is independently —H or —(C1-C6)alkyl;
• each R7 is independently —H or —(C1-C6)alkyl;
• each R8 is independently —(C1-C6)alkyl, —(C3-C10)-cycloalkyl, (C6-C10)-aryl, or 5- to 10-membered heteroaryl, wherein each occurrence of R8 is independently substituted with 0-5 R′;
• each R is independently selected from:
• H—,
• (C1-C12)-aliphatic-,
• (C3-C10)-cycloalkyl-,
• (C3-C10)-cycloalkenyl-,
• [(C3-C10)-cycloalkyl]-(C1-C12)-aliphatic-,
• [(C3-C10)-cycloalkenyl]-(C1-C12)-aliphatic-,
• [(C3-C10)-cycloalkyl]-O—(C1-C12)-aliphatic-,
• [(C3-C10)-cycloalkenyl]-O—(C1-C12)-aliphatic-,
• (C6-C10)-aryl-,
• (C6-C10)-aryl-(C1-C12)aliphatic-,
• (C6-C10)-aryl-O—(C1-C12)aliphatic-,
• 3- to 10-membered heterocyclyl-,
• (3- to 10-membered heterocyclyl)-(C1-C12)aliphatic-,
• (3- to 10-membered heterocyclyl)-O—(C1-C12)aliphatic-,
• 5- to 10-membered heteroaryl-,
• (5- to 10-membered heteroaryl)-(C1-C12)-aliphatic-, and
• (5- to 10-membered heteroaryl)-O—(C1-C12)-aliphatic-;
• wherein said heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and SO2, and said heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
• wherein each occurrence of R is independently substituted with 0-5 R′;
• or when two R groups bound to the same atom, the two R groups may be taken together with the atom to which they are bound to form a 3- to 10-membered aromatic or non-aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and SO2, wherein said ring is optionally substituted with 0-5 R′, and wherein said ring is optionally fused to a (C6-C10)aryl, 5- to 10-membered heteroaryl, (C3-C10)cycloalkyl, or a 3- to 10-membered heterocyclyl;
• wherein each occurrence of R′ is independently selected from halogen, —R″, —OR″, oxo, —CH2OR″, —CH2NR″2, —C(O)N(R″)2, —C(O)OR″, —NO2, —NCS, —CN, —CF3, —OCF3 and —NR2;
• wherein each occurrence of R″ is independently selected from H, —(C1-C6)-alkyl, (C3-C6)-cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl-, (C6-C10)-aryl-, (5- to 10-membered heteroaryl)-(C1-C6)-alkyl-, (C6-C10)-aryl-(C1-C6)-alkyl-, (5- to 10-membered heteroaryl)-O—(C1-C6)-alkyl-, or (C6-C10)-aryl-O—(C1-C6)-alkyl-.

The compound according to 53, wherein:

• m is 0, 1 or 2;
• when m is 1 or 2, at least one occurrence of R1 is halogen or —O((C1-C6)alkyl);
• R2 is selected from:
• —(C1-C6)alkyl, (C6-C10)-aryl-(C1-C12)aliphatic-, (C6-C10)aryl-O—(C1-C12)aliphatic-, (5- to 10-membered heteroaryl)-(C1-C12)aliphatic-, and (3- to 10-membered heterocyclyl)-(C1-C12)aliphatic-, wherein R2 is independently substituted with 0-3 R′;
• R3 is halogen, —CN, —C(O)NH2, —(C1-C6)alkyl, —C(O)((C1-C6)alkyl), —C(O)O((C1-C6)alkyl), —SO2(Ph(Me)),
• wherein R3 is independently substituted with 0-3 R′, and wherein R9 is selected from —H, —Me, —Et, —CF3, isopropyl, —OMe, -tert-butyl and cyclopropyl;
• R4 and R5 are both —H;
• and
• R6 is —H.

A compound selected from:

• Compound
• Structure
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 44
• 45
• 46
• 47
• 48
• 49
• 50
• 51
• 52
• 53
• 54
• 55
• 56
• 101
• 102
• 103
• 104
• 105
• 106
• 107
• 108
• 109
• 110
• 111
• 112
• 113
• 114
• 115
• 116
• 117
• 118
• 119
• 120
• 121
• 122
• 123
• 124
• 125
• 126
• 127
• 128
• 129
• 130
• 131
• 132
• 133
• 134
• 135
• 136
• 137
• 138
• 139
• 140
• 141
• 142
• 143
• 144
• 145
• 146
• 147
• 148
• 149
• 150
• 151
• 152
• 153
• 154
• 155
• 156
• 157
• 158
• 159
• 160
• 161
• 162
• 163
• 164
• 165
• 166
• 167
• 168
• 169
• 170
• 171
• 172
• 173
• 174
• 175
• 176
• 177
• 178
• 179
• or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof.